Abstract
Selective CDK7 inhibition has been shown to target two fundamental processes in cancer: transcription and cell cycle control. SY-5609 is a potent and selective CDK7 inhibitor in Ph1 clinical development in patients with advanced solid tumors including ovarian cancer (NCT04247126). Here we report on the impact of intermittent SY-5609 dosing regimens on tumor growth inhibition (TGI), pharmacodynamic (PD) activity, and pharmacokinetics (PK) in a xenograft model of high grade serous ovarian cancer (HGSOC).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
